Cargando…
Drugging SUMOylation for neuroprotection and oncotherapy
Autores principales: | Bernstock, Joshua D., Ye, Daniel G., Lee, Yang-ja, Gessler, Florian, Friedman, Gregory K., Zheng, Wei, Hallenbeck, John M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5900498/ https://www.ncbi.nlm.nih.gov/pubmed/29623920 http://dx.doi.org/10.4103/1673-5374.228718 |
Ejemplares similares
-
Topotecan is a potent inhibitor of SUMOylation in glioblastoma multiforme and alters both cellular replication and metabolic programming
por: Bernstock, Joshua D., et al.
Publicado: (2017) -
Global SUMOylation is a molecular mechanism underlying hypothermia-induced ischemic tolerance
por: Lee, Yang-ja, et al.
Publicado: (2014) -
SUMOylation in Glioblastoma: A Novel Therapeutic Target
por: Fox, Brandon M., et al.
Publicado: (2019) -
SUMOylation promotes survival and integration of neural stem cell grafts in ischemic stroke
por: Bernstock, Joshua D., et al.
Publicado: (2019) -
A novel quantitative high-throughput screen identifies drugs that
both activate SUMO conjugation via the inhibition of microRNAs 182 and 183 and
facilitate neuroprotection in a model of oxygen and glucose
deprivation
por: Bernstock, Joshua D, et al.
Publicado: (2015)